Oncolytics Biotech Inc. Files 20-F Report for Fiscal Year Ended December 31, 2023

TL;DR

<b>Oncolytics Biotech Inc. has submitted its 2023 annual 20-F report detailing its financial and operational status.</b>

AI Summary

ONCOLYTICS BIOTECH INC (ONCY) filed a Foreign Annual Report (20-F) with the SEC on March 12, 2024. Oncolytics Biotech Inc. filed its annual 20-F report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is located at 804, 322 - 11 Avenue SW, Calgary, Alberta, T2R 0C5. The filing is made under the Securities Exchange Act of 1934. Oncolytics Biotech Inc. is classified under the Pharmaceutical Preparations industry (SIC code 2834).

Why It Matters

For investors and stakeholders tracking ONCOLYTICS BIOTECH INC, this filing contains several important signals. This filing provides a comprehensive overview of the company's performance and financial position for the fiscal year 2023, which is crucial for investors to assess the company's health and future prospects. As a 20-F filing, it offers detailed information required for foreign private issuers, including financial statements and business descriptions, enabling a deeper understanding of Oncolytics Biotech's operations and regulatory compliance.

Risk Assessment

Risk Level: low — ONCOLYTICS BIOTECH INC shows low risk based on this filing. The filing is a routine annual report (20-F) and does not contain new material events or significant financial changes that would indicate elevated risk.

Analyst Insight

Investors should review the detailed financial statements and business overview within the 20-F filing to understand Oncolytics Biotech's performance and strategic direction for 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-12 — Filed As Of Date (Date the filing was submitted)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
• 001-38512 — SEC File Number (SEC filing identifier)

Key Players & Entities

• ONCOLYTICS BIOTECH INC (company) — Filer name
• 2024-03-12 (date) — Filing date
• 2023-12-31 (date) — Conformed period of report
• 0001129928-24-000018 (other) — Accession number
• 804, 322 - 11 AVENUE SW (address) — Business address street
• CALGARY (address) — Business address city
• T2R 0C5 (address) — Business address zip
• 4036707380 (phone) — Business phone

FAQ

Industry Context

Oncolytics Biotech Inc. operates within the pharmaceutical preparations industry, focusing on the development of novel cancer therapies.

Regulatory Implications

As a foreign private issuer, Oncolytics Biotech Inc. is subject to specific SEC reporting requirements, including the annual filing of Form 20-F.

What Investors Should Do

1. Review the detailed financial statements and management discussion in the 20-F filing.
2. Analyze the company's business overview and risk factors for the fiscal year 2023.
3. Compare the 2023 performance metrics with previous years to identify trends.

Key Dates

• 2024-03-12: Filing Date — Submission of the annual 20-F report for fiscal year 2023.
• 2023-12-31: Fiscal Year End — End date of the reporting period covered by the 20-F.

Year-Over-Year Comparison

This is the annual 20-F filing for the fiscal year ended December 31, 2023, providing updated information compared to previous filings.

Filing Documents

• oncyf-20231231.htm (20-F) — 1706KB
• ex21exdescriptionofsecurit.htm (EX-2.1) — 3KB
• ex412employmentagreementam.htm (EX-4.12) — 242KB
• ex413-amylevinamendment1xe.htm (EX-4.13) — 35KB
• ex80subsidiaries2023.htm (EX-8.0) — 3KB
• ex121ceocertification2023.htm (EX-12.1) — 10KB
• ex122cfocertification2023.htm (EX-12.2) — 10KB
• ex131ceocertification2023.htm (EX-13.1) — 5KB
• ex132cfocertification2023.htm (EX-13.2) — 5KB
• ex151-2023mda.htm (EX-15.1) — 348KB
• ex152ey2023consent.htm (EX-15.2) — 5KB
• ex161-corptradingpolicyrev.htm (EX-16.1) — 63KB
• ex971oncolyticsclawbackpol.htm (EX-97.1) — 36KB
• oncolyticslogotaglinebluea.jpg (GRAPHIC) — 359KB
• oncolyticspipelineye2.jpg (GRAPHIC) — 635KB
• oncyf-20231231_g1.jpg (GRAPHIC) — 145KB
• oncyf-20231231_g2.jpg (GRAPHIC) — 450KB
• 0001129928-24-000018.txt (&nbsp;) — 11130KB
• oncyf-20231231.xsd (EX-101.SCH) — 73KB
• oncyf-20231231_cal.xml (EX-101.CAL) — 48KB
• oncyf-20231231_def.xml (EX-101.DEF) — 258KB
• oncyf-20231231_lab.xml (EX-101.LAB) — 573KB
• oncyf-20231231_pre.xml (EX-101.PRE) — 429KB
• oncyf-20231231_htm.xml (XML) — 1075KB

o Item 18 o

Item 17 o Item 18 o If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ONCOLYTICS BIOTECH INC. FORM 20-F TABLE OF CONTENTS

Identity of Directors, Senior Management and Advisers

Item 1. Identity of Directors, Senior Management and Advisers 6

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable 6

Key Information

Item 3. Key Information 6

Information on the Company

Item 4. Information on the Company 27

Unresolved Staff Comments

Item 4A. Unresolved Staff Comments 38

Operating and Financial Review and Prospects

Item 5. Operating and Financial Review and Prospects 38

Directors, Senior Management and Employees

Item 6. Directors, Senior Management and Employees 39

Major Shareholders and Related Party Transactions

Item 7. Major Shareholders and Related Party Transactions 51

Financial Information

Item 8. Financial Information 53

The Offer and Listing

Item 9. The Offer and Listing 53

Additional Information

Item 10. Additional Information 53

Quantitative and Qualitative Disclosures About Market Risk

Item 11. Quantitative and Qualitative Disclosures About Market Risk 64

Description of Securities Other Than Equity Securities

Item 12. Description of Securities Other Than Equity Securities 65

Defaults, Dividend Arrearages and Delinquencies

Item 13. Defaults, Dividend Arrearages and Delinquencies 65

Material Modifications to the Rights of Security Holders and Use of Proceeds

Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 65

Controls and Procedures

Item 15. Controls and Procedures 65

[Reserved]

Item 16. [Reserved] 66

Audit Committee Financial Expert

Item 16A. Audit Committee Financial Expert 66

Code of Ethics

Item 16B. Code of Ethics 66

Principal Accountant Fees and Services

Item 16C. Principal Accountant Fees and Services 66

Exemptions from the Listing Standards for Audit Committees

Item 16D. Exemptions from the Listing Standards for Audit Committees 67

Purchase of Equity Securities by the Issuer and Affiliated Purchases

Item 16E. Purchase of Equity Securities by the Issuer and Affiliated Purchases 67

Change in Registrant's Certifying Accountants

Item 16F. Change in Registrant's Certifying Accountants 67

Corporate Governance

Item 16G. Corporate Governance 67

Mine Safety Disclosure

Item 16H. Mine Safety Disclosure 67

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 68

Insider Trading Policies

Item 16J. Insider Trading Policies 68

Cybersecurity

Item 16K. Cybersecurity 68

Financial Statements

Item 17. Financial Statements 69

Financial Statements

Item 18 Financial Statements 69

Exhibits

Item 19. Exhibits 69

Financial Statements

Financial Statements F1 - F27 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS All references in this annual report on Form 20-F to the terms "we," "our," "us," "the Company," and "Oncolytics" refer to Oncolytics Biotech Inc. Unless otherwise indicated, all references to "$" and "dollars" in this annual report mean Canadian dollars. Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words "expects," "anticipates," "believes," "intends," "estimates," "projects", "potential", "possible" and similar expressions, or that events or conditions "will," "may," "could" or "should" occur. The forward-looking statements in this annual report on Form 20-F are subject to various risks and uncertainties, mos

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not Applicable.

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not Applicable.

KEY INFORMATION

ITEM 3. KEY INFORMATION A. [RESERVED] B. Capitalization and Indebtedness Not Applicable. C. Reasons for the Offer and Use of Proceeds Not Applicable. D. Risk Factors Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this annual report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results, or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. Research and Development Risks All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially. Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commer

View Full Filing

View this 20-F filing on SEC EDGAR